GlassScriptPhysician profile
Ashley Atkinson
NPI 1578003133
$7,171.83
in general payments reported to CMS, 2019-2025
34 companies · $1,219 in 2025
The $1,219 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,032 · 2022: $1,674 · 2023: $1,075 · 2024: $1,171 · 2025: $1,219.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,420 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,420.18 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,836.20 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,046.29 | 2021-2025 | |
| Lilly USA, LLC | $971.87 | 2021-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $316.93 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Amarin Pharma, INC. | $286.28 | 2021-2022 | |
| Abbott Laboratories | $276.94 | 2021-2025 | Freestyle Libre 3 |
| Amgen INC. | $254.00 | 2021-2025 | Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $226.14 | 2021-2022 | |
| Glaxosmithkline, LLC. | $223.10 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $164.96 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $154.05 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $128.59 | 2021 | |
| Exact Sciences Corporation | $122.95 | 2023-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $119.04 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $118.65 | 2021-2023 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $107.15 | 2021-2025 | Spectra Wavewriter, Wavewriter Alpha Prime 16 |
| Biohaven Pharmaceutical Holding Company LTD. | $102.10 | 2022 | |
| Esperion Therapeutics, INC. | $81.40 | 2021 | |
| Corcept Therapeutics | $78.57 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $72.60 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $67.01 | 2023 | Quviviq |
| Pfizer INC. | $59.67 | 2023-2025 | |
| Eisai INC. | $48.67 | 2021 | |
| Sanofi-Aventis U.S. LLC | $46.24 | 2021-2022 | |
| Dexcom, INC. | $42.56 | 2021-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $39.90 | 2021 | |
| Currax Pharmaceuticals LLC | $30.81 | 2022-2024 | Contrave |
| Vanda Pharmaceuticals INC. | $29.87 | 2025 | Fanapt |
| Vertex Pharmaceuticals Incorporated | $24.22 | 2024 | |
| Biohaven Pharmaceuticals, INC. | $24.11 | 2021 | |
| Aimmune Therapeutics, INC. | $22.80 | 2025 | Vowst |
| Alkermes, INC. | $19.46 | 2021 | |
| Genentech USA, INC. | $14.37 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Atkinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.